AMU, AP-HM, VRCM
Education is also one of the strategic components of the Marseille Immunopole project
Advances in science and technology have gradually abolished the frontier between fundamental research and the clinic. Like most founders of Marseille Immunopole, my every day life consists in constant back and forth between the laboratory and the patient’s bedside and I work at the interface of several disciplines, technologies and application fields: immunology and haematology, cell therapy and monoclonal antibodies, diagnosis and therapy. We work also, of course, with industry that now constitutes a key player to accelerate the transfer of these innovations to the clinic.
My common theme remains the vessel. In VRCM, vessels can be destroyed to starve tumours or conversely rebuilt to restore blood flow in ischemic stroke, lower extremity arterial diseases, etc. With the haematology service of the Conception Hospital, we have also developed innovative vascular biomarkers by measuring the concentration and origin of blood microparticles released by damaged cells, so clinicians can now improve the diagnosis and monitoring of patients with cardiovascular diseases, cancers, autoimmune and inflammatory diseases.
With the cell therapy unit of Florence Sabatier, our team is also involved in regenerative medicine. We base this on an unexplored source of stem cells that lies at the core of adipose tissue: the stromal vascular fraction. The early clinical data we have obtained from scleroderma, a rare and debilitating autoimmune disease, seem already to confirm the potential of this new approach. Education is also one of the strategic components of the Marseille Immunopole project. As Dean of the Faculty of Pharmacy, my goal is also to prepare the next generation: to fuel research and industry with new talent, but also to familiarise future pharmacists with new drugs arising from these innovations.#clinic
Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.
Immunotherapy is expanding to other cancers types: kidney cancer, bladder cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma… but we are still only at the beginning of the story!
Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.
AMU, IPC, CRCM
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.